Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156789 | 0.90 | LMNA (0.39) | PTGDR2NOD2NOD1ALDH1A1LMNA | |
| SCHEMBL1156624 | 0.90 | CHRM5 (0.43) | HTR6LMNAKMT2ACHRM5 | |
| SCHEMBL4569737 | 0.89 | PTGDR (0.42) | PTGDR2HTR6ALDH1A1LMNAPTGDR | |
| SCHEMBL4411754 | 0.88 | CHRM5 (0.42) | HTR6LMNAKMT2ACHRM5 | |
| SCHEMBL1157013 | 0.88 | CHRM5 (0.46) | PTGDR2HTR6PTGDRTAS2R14CHRM5 | |
| SCHEMBL1278234 | 0.84 | PTGDR2 (0.35) | PTGDR2ALDH1A1LMNACHRM5 | |
| SCHEMBL1156488 | 0.83 | CHRM5 (0.36) | PTGDR2ALDH1A1KMT2ACHRM5 | |
| SCHEMBL1156168 | 0.83 | KMT2A (0.46) | PTGDR2HTR6ALDH1A1KMT2A | |
| SCHEMBL1156564 | 0.82 | LMNA (0.41) | PTGDR2HTR6ALDH1A1LMNACYP3A4 | |
| SCHEMBL1278354 | 0.82 | TAS2R14 (0.40) | ALDH1A1LMNATAS2R14KMT2ACHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048909-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028476-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | PTGDR2 606/4885HTR6 1412/4885NOD2 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.